Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting tweet from Sheff on PAVM: "
$PAVM..$1.58..new CCO on board and all of the documents submitted to the FDA. Most likely decision mid-late August at latest is company safe bet. 510k’s don’t give specific dates but the new CCO isn’t at the office twiddling his thumbs for nothing! Decision could come anytime."
https://twitter.com/SheffStation/with_replies
I have a theory that shorts that follow Sheff, and his tweets, put in a quick bear raid to shake the momo types that could get scared out or had stops set. Just a theory.
Stocktwits watchers are going up 200 a day lately: now 2362. PAVM is like NBEV was in the beginning when it exploded in watchers, but PAVM has way more sales potential in the immediate future with total addressable markets in the billions.
Trading volume is increasing and it's starting to show up on the radar. Tute ownership at 6.49% as of now, big players took little bites into it: https://www.nasdaq.com/symbol/pavm/institutional-holdings
Looking at the thousands of pharmacies in the U.S., it's easy to see where pharmacists/the minute clinics will be used to test patients with the Eso-Check as CPT codes will allow the pharmacies to be paid for the procedure. This is huge as Walgreens, CVS, and others will be on top of this as the Eso-Check provides an extremely valuable medical service that they can leverage their clinics to perform and increases their margins. It won't make traditional doctors happy, but it's good for PAVM.
What is very impressive is that Eco-Check needed to have diverse testing in multi-centers with a heterogenous population in order to have the highest probability of FDA approval. So Case Western along with Lucid was able to get NIH support for the study along with great institutions to clinically test the Eso-Check. That's a hell of an accomplishment and shows that the Eso-Check is a priority and fills an unmet need with all of the benefits we have talked about. That is serious stuff. Lucky to be here at the beginning instead of wondering if I should buy it when it's at $15. Timing is everything.
This is a must ready for newbies and longs:
PavMed Spinoff Lucid Diagnostics Aims to Market Molecular
Barrett's Esophagus Test in 2019
May 29, 201
8
|
John Gilmore
This article has been updated from a previous version which misstated the potential price of
an EsoCheck test.
NEW YORK (GenomeWeb)
–
Announcing a
partnership
with Case Western Reserve
University earlier this month, PavMed will enter the cance
r detection market with its new
subsidiary Lucid Diagnostics. The subsidiary will commercialize CWRU's EsoCheck
technology, which is a squamous
-
cell based test that detects Barrett's esophagus (BE), a
precursor to esophageal adenocarcinoma (EAC).
PavMed's
EsocheckRapid test includes a non
-
invasive cell sampling device and a
diagnostic test for two methylated DNA biomarkers. Recently formed Lucid anticipates
releasing a commercial test in the first quarter of 2019.
Standard detection for BE involves a clinic
ian performing endoscopy, which uses a thin,
flexible tube to search for inflammation, ulcers, and tumors. While endoscopy is effective for
diagnosing conditions like esophageal cancers, it is invasive and could cost up to$3000 per
procedure, according to
Amitabh Chak, co
-
inventor of the technology and a professor of
medicine at CWRU. This also deters BE detection until visible symptoms occur, which may
be too late in up to 95 percent of cases of EAC.
Chak explained that the sample collection process for th
e EsoCheck technology involves a
patient swallowing a capsule containing an inflatable balloon. After the capsule arrives in
the stomach, the balloon inflates and is slowly pulled through the lower esophagus. Once
the endoscopist feels the esophagus constr
ict around the balloon, he then deflates the
collection device using an attached syringe and retracts the balloon inside the capsule.
According to Chak, the technician would then "slice the balloon off the capsule, freeze it,
[and] extract DNA using a buff
er," then send the sample to a reference lab for PCR and
next
-
generation sequencing. Chak noted that on average, the initial sample collection step
takes around five minutes.
Regarding the DNA biomarker portion of the assay, Sanford Markowitz, an EsoCheck
co
-
inventor and professor of cancer genetics at CWRU, had shown with others over a decade
ago that one of the biomarkers, methylated vimentin gene (mVIM), is an indicator of
colorectal cancer. Markowitz and his team found that the biomarker also occurs in
precancerous esophagus lesions and began developing a test for BE based on the
biomarker.
The researchers subsequently added another DNA biomarker, work that
was published
in
Jan
uary in
Science Translational Medicine
. Specifically, the team performed genome
-
wide
screening in squamous cell samples to find regions targeted for recurrent aberrant cytosine
methylation in BE, identifying high
-
frequency methylation within the
CCNA1
locu
s. The team
tested
CCNA1
DNA methylation as a BE biomarker in cytology brushings of the distal
esophagus of 173 individuals with or without BE, and found that the biomarker performed
identically to mVIM.
When Chak and his team combined both biomarkers in a
next
-
generation bisulfite
sequencing assay, they were able to detect both BE and EAC with 95 percent sensitivity
and 91 percent specificity in a multicenter clinical study of 408 patients. Chak noted that the
test's detection was comparable to endoscopy
-
d
irected brushings.
The overall process
—
sample collection, PCR amplification, next
-
generation sequencing,
and automated software analysis
—
currently requires about a three
-
to four
-
day turnaround
time.
Limitations of the study included the fact that samp
le collection with the balloon device only
occured at a single institution, so the researchers will need to repeat the procedure in other
centers and in community
-
based populations. The team's study also included mostly male
Caucasians due to the high prev
alence of BE in the targeted population. Chak noted that
his team will need to repeat the study in female and other ethnic groups to generate
widespread results.
In addition, the team encountered failures in patient groups to swallow the ballon device or
o
btain enough cell samples, shortcomings that will be a main focus of improvement in future
studies.
Chak said that his team has filed for several patents regarding the technology, including a
provisional patent for the balloon device in addition to using t
he
CCNA1
biomarker for BE.
Since the team published the paper in January, it has initiated a large, multicenter, National
Institutes of Health
-
supported study with five other research organizations
—
the Cleveland
Clinic, Johns Hopkins, Mayo Clinic, Washin
gton University in St. Louis, and the University of
North Carolina
—
in order to establish clinical evidence for EsoChek's widespread use as a
screening test for BE.
PavMed also spun off Lucid, which licensed the technology from CWRU to develop
Esocheck to
diagnose BE in patients with inflammation caused by acid reflux in the
esophagus. Lucid will primarily market the diagnostic test toward Caucasian males in their
fifties and older, where heartburn and BE most often occur. PavMed CEO and Chairman
Lishan Ak
log said that he believes the patient population that the test could potentially help
diagnose will be well over 50 million individuals.
Several other research groups and firms have been developing similar technology to
diagnose BE and predict EAC. Researc
hers at Columbia University have
recently
performed next
-
generation sequencing
on pre
-
cancerous form
alin
-
fixed, paraffin
-
embedded tissues in patients with Barrett's intestinal metaplasia, which is related to BE.
The group found mutations in TP53, APC, CDKN2A, KRAS, FGFR, and PDGFRA genes.
In addition, Medtronic Solutions has commercialized the
Cytosponge
test, which involves a
patient swallowing a gelatin
-
covered capsule attached to a stri
ng. Traveling down into the
stomach, the capsule expands into a small mesh balloon sponge. The clinician then pulls
balloon out of the stomach with an attached string, collecting squamous cells while it passes
through entire esophagus.
Aklog argued that me
thods like Cytosponge lack the ability to perform targeted sampling in
the lower esophagus, where BE normally occurs. In addition, he pointed out that
Cytosponge deals with contamination from other cells in the esophagus. Instead of being
paired with defin
itive biomarkers, the test requires a cytologist to examine the sponge to find
cells that indicate BE from an array of different cells.
"This is important, since if you're not getting a pure sampling of the cells from the lower
esophagus, you're dependent
on expensive cytology," Aklog noted.
In contrast, Aklog highlighted that the Esocheck test delivers accurate, automated results
and does not require an operator for cell detection. Lucid removes the pathologist from the
equation by sending the specimen to
a reference lab, where researchers perform PCR
amplification and sequencing on the sample. Using a customized algorithm to track the
number of methylated sites per cell, the researchers can detect whether the patient has BE
and decide the patient's risk po
tential for EAC.
Aklog said that Lucid is aiming to receive both US FDA 510(k) approval for its EsoCheck
device and CLIA/CAP approval for its reference laboratory by the end of the year. The firm
is targeting the first quarter of 2019 for an initial commer
cial launch of EsoCheck as an LDT
product.
While declining to disclose the test's price, Aklog said that EsoCheck will be much cheaper
than a standard endoscopy.
Aklog also sees an opportunity for the device to monitor BE's eventual progression to
cancer
. If patients have been identified with BE but do not have a high
-
enough threshold for
intervention, researchers could perform the relatively inexpensive procedure every six
months instead of an endoscopy to track the condition's progression.
In addition,
Aklog also envisions applying the EsoCheck technology to diseases like
esophageal squamous cell carcinoma
—
caused by excessive smoking or alcohol use
—
in
vulnerable populations. By using biomarkers commonly used for cancer detection, Aklog
believes the te
chnology could expand in scope and be performed on patients with a variety
of cancers.
"If the balloon device could be used with some procedural alterations, [we] could screen for
cells in different populations," he said. However, "we will need to line up
the [test] with a
biomarker that detects the precursor to the condition."
Initially, Lucid will focus on patients scheduled for endoscopies. If EsoCheck produces
positive results, then the patient can pursue endoscopy for further validation. If the test is
negative, the clinician can later follow up with an additional procedure
in six months to see if
the patient's risk has elevated.
Aklog said that the firm hopes to offer doctors the ability to screen anyone with frequent
(more than once a week) heartburn for BE, which could qualify up to 20 million patients. In
addition, clinic
ians could eventually screen patients who are at risk for the condition but do
not exhibit symptoms.
"Up to 40 percent of patients have acid reflux but do not have symptoms, and therefore the
risk is worrisome for populations with the potential risk," Aklo
g explained.
"If we can prove the value of such a simple, non
-
invasive method ... imagine seeing the test
in a pharmacy," Aklog said. " You come in for your your fourth refill of Prilosec or Nexium,
and the pharmacist might say 'You want to get this test d
one, which we can do on the spot.'
"
Lucid is currently engaged in internal conversations about a potential Series A funding
round. In the long term, PavMed will look at market conditions and its own capital position to
decide whether it will raise money o
r self
-
fund Lucid. In addition, Lucid has entered a
managing service agreement with PavMed.
"Over time, as we get to commercialization, Lucid will build out its own independent
management team," Aklog said.
According to Aklog, Lucid aims to initially launc
h the product using independent distributors
or through a partnership with a larger company in the US, rather than spending capital to
build an internal capital sales force. The test has also received interest from international
partners, with particular i
nterest from European groups, Aklog noted.
https://pavm.investorhq.businesswire.com/sites/pavm.investorhq.businesswire.com/files/doc_library/file/PavMed_Spinoff_Lucid_Diagnostics_Aims_to_Market_Molecular_Barretts_Esophagus_Test_in_2019.2.pdf
The interesting part is that Lucid subsidiary is owned 80% by PAVM, and could potentially be spun off someday so it could become a public company and benefit the PAVM shareholders. A potential future carrot for current stockholders.
PAVMZ and PAVMW warrant details. .
PAVMZ – publicly traded series Z warrant has an exercise price of $1.60 with the following terms – you can also view this information that was included in an SEC filing on June 1, 2018 regarding Form 423B3 Prospectus – page 5 - http://ir.pavm.com/sec-filings:
Each Series Z Warrant, listed for trading on Nasdaq under the symbol “PAVMZ”, entitles the holder to purchase one share of common stock at an exercise price of $1.60 per share from the date on which the Series Z Warrant is issued through its expiration on April 30, 2024, or earlier upon certain redemption provisions. Commencing on the first anniversary of the issuance date of the Series Z Warrants, the Company may redeem the outstanding Series Z Warrants, at the Company’s option, in whole or in part, at a price of $0.01 per warrant: at any time while the warrants are exercisable; upon a minimum of 30 days’ prior written notice of redemption; if, and only if, the volume weighted average closing price of the Company’s common stock equals or exceeds $9.00 (subject-to adjustment) for any 20 out of 30 consecutive trading days ending three Business Days before the Company issues its notice of redemption, and provided the average daily trading volume in the stock is at least 20,000 shares per day; and, if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.
PAVMW – publicly traded series W warrant has an exercise price of $5.00 with the following terms – as more fully described in our Annual Report on Form 10-K filed with the SEC
· The Series W Warrants have an exercise price of $5.00 per share, with such exercise price not subject to further adjustment, except in the event of stock dividends, stock splits or similar events affecting the common stock, and became exercisable on October 28, 2016 and expire on January 29, 2022, or earlier upon redemption by the Company, as discussed below.
Commencing April 28, 2017, the Company may redeem the outstanding Series W Warrants (other than those outstanding prior to the IPO held by the Company’s management, founders, and members thereof, but including the warrants held by the initial investors), at the Company’s option, in whole or in part, at a price of $0.01 per warrant: at any time while the warrants are exercisable; upon a minimum of 30 days’ prior written notice of redemption; if, and only if, the volume weighted average price of the Company’s common stock equals or exceeds $10.00 (subject-to adjustment) for any 20 consecutive trading days ending three business days before the Company issues its notice of redemption, and provided the average daily trading volume in the stock is at least 20,000 shares per day; and, if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants. The right to exercise will be forfeited unless the IPO Warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of an IPO Warrant will have no further rights except to receive the redemption price for such holder’s IPO Warrant upon surrender of such warrant.
Dennis McGrath
Chief Financial Officer
NASDAQ: PAVM
One Grand Central Place, Suite 4600
New York, NY 10165
Tel: 212-949-4319
mobile: 609-432-6861
The Esochek test, sounds like a very promising possibility. The device is very sensitive and specific for testing. Assuming it works well, it helps to fill an unmet need. It saves a ton of time and money vs the current standard of treatment which involves so many procedural layers. Could be a grand slam.
The addressable market for the test is very large as in millions of possible patient candidates. The overall benefits of the Esochek makes for viable consideration of using the test vs the impractical, ultra expensive, time consuming testing protocol that currently exists.
If this pans out, we are in basically on the bottom floor of this company as an investment. I'm keeping my fingers crossed.
Look at her gooooooo. weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
PAVM has plenty of shots to goal to become successful in large markets. Just grabbing a small piece in each one gets them close to a half billion to a billion in sales. Lots of potential: http://www.pavmed.com/products/
These guys are super intelligent and have gone to the best schools for medical training. I like our chances: http://www.pavmed.com/team
Link to their last conference call: http://ir.pavm.com/event/conference-call/pavmed-inc-business-update-conference-call-3
I may buy some of the warrants in addition to the stock. Seems cheap at .519.
What do you make of Citron and its short on ABBV?
Thanks for the info. Very helpful.
Thanks for sharing! RVNC seems a much better opportunity
The question I have is: are you invested in it and at what avg price? TIA. I'm not touching it unless I know you are in it.
This company looks like it may be a gem. Noticed on Stocktwits the number of watchers has slowly increased to 101 from 60. Should get a lot of eyes on it if the e/r is good tomorrow. Very strong growth and EPS. Most undervalued with a low price to sales of 1.41. It should be double at 2.8 with a price in the $16 buck range. We shall see.
The King of Jordan visited the facilities and took a tour. He celebrated with the company as it was the first company from Jordan to be listed on the Nasdaq:
https://www.facebook.com/280867815729634/photos/pcb.389669114849503/389659444850470/?type=3&theater
Anybody try the Simple Truth Kombucha at Kroger? The formula tastes eerily similar to Bucha. It didn't have vinegar flavor and it had about the same amount of calories/carbs.
No tariffs for this company's produced goods... a profitable and growing business.... 1.5 million float... no body knows about this company....earnings next week. If all the usual chat rooms "discover this company next week, who knows what could happen. Very exciting times ahead.
Primarily manufactures outerwear for high profile, international brands - Profitable company with strong organic growth - Dedicated to high levels of quality control and meeting international manufacturing standards - Overseas production facilities located within a special free-trade zone allowing sales to the U.S. without tariff or quota restrictions - Received EU free tariff privilege in December 2017 - Completion of factory expansion in 2017 increased capacity to accommodate additional growth - Full package production operations allow company to capture value from entire manufacturing production chain (sourcing, logistics, cut, make, trim, embroidery, finishing, inspection, and packaging) - Strong development capabilities in converting designs to mass production.
Jerash Begins Trading on NASDAQ
First Jordanian Company to List on Nasdaq Now Trading Under the Symbol JRSH
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Jerash Holdings (US), Inc. (NASDAQ: JRSH) (the "Company"), a producer of high quality textile goods for leading global brands, has commenced trading of its common stock on the Nasdaq Capital Market under the symbol JRSH.
Highlights:
Jerash is believed to be the first Jordanian company to list on a major US exchange. The company recently completed its IPO, raising more than $10 million in growth capital.
Jerash is principally engaged in the manufacturing and exporting of customized, ready made sport and outerwear goods from knitted fabrics.
The company provides manufacturing services utilized by many well-known brands and retailers, such as Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation (which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, etc.), and Philip-Van Heusen (which owns brands such as Calvin Klein, Tommy Hilfiger, IZOD, Speedo, etc.).
Jerash's facilities and workforce are located within a special free
trade zone allowing sales to the U.S. without tariff or quota restrictions.
The company owns three factory units and two warehouses and employs approximately 2,700 people. The total annual capacity at its facilities is approximately 6.5 million pieces.
The company is engaged in socially responsible employment practices, including the provision of jobs to Syrian refugees residing in Jordan. Jerash maintains a number of Jordanian and international certifications attesting to its production and workforce programs.
Revenue in Fiscal 2017, ended March 31, 2017, was $62.0 million, an increase of 18% year over year, and net profit was $10.6 million.
Through the first nine months of fiscal 2018, Jerash has reported revenue of $60.4 million, and net income of $11.4 million.
The company expects to report its financial results for Fiscal 2018, which ended March 31, 2018, in June.
On May 2, the company announced the closing of its "best efforts" initial public offering of common stock, at a price of $7.00 per share (the "offering"). The Company sold the maximum amount of shares in the oversubscribed offering, or 1,430,000 shares, for total gross proceeds to the Company of approximately $10,010,000 before deducting offering expenses. The company intends to use the proceeds of the offering as growth capital to build or acquire additional production capacity to meet rising demand for its production services.
A registration statement relating to these shares was declared effective by the Securities and Exchange Commission on March 14, 2018 (File No. 333-222596). The offering was made only by means of a written prospectus forming part of the registration statement. The final prospectus and any prospectus supplements relating to the offering are also available on the SEC's website at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jerash Holdings (US), Inc.
Jerash Holdings (US), Inc. (NASDAQ: JRSH) is a manufacturer utilized by many well-known brands and retailers, such as Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation (which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, etc.), and Philip-Van Heusen (which owns brands such as Calvin Klein, Tommy Hilfiger, IZOD, Speedo, etc.). Its production facilities are made up of three factory units and two warehouses and employ approximately 2,700 people. The total annual capacity at its facilities is approximately 6.5 million pieces. Additional information is available at http://www.jerashholdings.com.
Contact:
Richard J. Shaw, Chief Financial Officer
(315) 727-6791
richard.shaw@jerashholdings.com
Matt Kreps, Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
SOURCE: Jerash Holdings (US) Inc.
This recent IPO, is a strong, growing, profitable company providing clothing to major retail operations from Jordan, a free trade zone (Trump, China, and EU tariffs don't apply). The micro-float, about 1.5 million shares, and the company flying under the trader/investor radar, makes this company a prime target for a run imo. Building a position in the 8's and 9's as we speak.
View the investor presentation:
https://s3.amazonaws.com/cdn.irdirect.net/PIR/1093/2598/Jerash%20Final%20Investor%20Presentation%203.14.18.PDF
I'm bummed. Sold at the open after reading the 8K. Geez, was hoping for $3 in a day or two. Now all I can see is 1.89 conversion price in my head. I suspect shorts will hammer this down into the $1's. Have to see what happens with the long term loan and whether the dilution can be rescinded from the bridge loan.
"$3 by July 15...probably sooner than that". Joe knows!
New Age Beverages Corporation Closes New $4.75 Million Financing Facility
Published: June 21, 2018 6:30 a.m. ET
June 21, 2018 (ACCESSWIRE via COMTEX) -- DENVER, CO / ACCESSWIRE / June 21, 2018 / NEW AGE BEVERAGES CORPORATION NBEV, +20.19% the Colorado-based organic and natural healthy functional beverage company dedicated to making a difference for consumers with better-for-you alternatives, today announced the closing of a $4.75 million debt financing.
KEY HIGHLIGHTS:
8% interest note provides immediate working capital to purchase inventory and continue to meet the needs of New Age's expanded distribution and customer base Short-term financing intended to be replaced with permanent asset-based facility currently being finalized
The bridge financing provides for the immediate purchase of inventory and working capital needs in a major current ramp-up period for the Company. $2 million of the proceeds will be used to eliminate the Company's current line of credit with US Bank, with the remainder of the proceeds being utilized for inventory. New Age expects to replace this current short-term financing with a more substantial and lower cost three-year asset-based credit facility that it is currently in the process of being documented.
Chuck Ence, CFO of New Age Beverages commented, "The new credit facility comes at the right time for our Company and allows us to continue the progress we have made in our expanded distribution. Our capital need is a good problem to have as the reorders on our brands from major customers and distributors have been robust, especially on our new, higher margin products. This facility, although short-term, will bridge our working capital requirements until we finalize our new permanent facility, which we believe will satisfy our working capital needs for the foreseeable future."
About New Age Beverages Corporation (NASDAQ: NBEV)
New Age Beverages Corporation is a Colorado-based healthy functional beverage company that was created in 2016 and 2017 with the combination of Búcha Live Kombucha®, XingTea®, Coco-Libre®, and Marley®, to create a one-stop-shop solution for retailers and distributors providing healthier beverages in the disruptive growth segments of the $870 Billion-dollar non-alcoholic beverage industry. In that period, New Age has become the 54th largest beverage company, the 8th largest healthy beverage company, and the fastest growing in the world. New Age competes Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks, Coconut Waters, Functional Waters, and Rehydration Beverages with the brands Búcha® Live Kombucha, XingTea®, XingEnergy®, Marley One Drop®, Marley Mellow Mood®, Marley Mate™, Marley Cold Brew™, Coco-Libre®, PediaAde™, and Aspen Pure® PH and Aspen Pure® Probiotic Water. The Company's brands are sold across all 50 states within the US and in more than 10 countries internationally across all channels via direct and store door distribution systems. The company operates the websites www.newagebev.com, www.newagehealth.us, www.mybucha.com, www.xingtea.com, www.aspenpure.com, www.drinkmarley.com, www.cocolibre.com, and https://shop.newagebev.com.
New Age has exclusively partnered with the world's 5th largest water charity, WATERisLIFE, to end the world water crisis with the most innovative technologies available. Donate at WATERisLIFE.com to help us #EnditToday.
Image: https://www.accesswire.com/uploads/Water.tif.jpg
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company including statements regarding New Age Beverage's expectation to see continued growth. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. New Age Beverages competes in a rapidly growing and transforming industry, and other factors disclosed in the Company's filings with the Securities and Exchange Commission might affect the Company's operations. Unless required by applicable law, NBEV undertakes no obligation to update or revise any forward-looking statements.
For investor inquiries about New Age Beverages Corporation please contact:
Cody Slach, Liolios Group, Inc.
Investor Relations Counsel
Tel 949-574-3860
NBEV@Liolios.com
New Age Beverages Corporation
Chuck Ence, CFO
303-289-8655
Cence@newagebev.com
SOURCE: New Age Beverages Corporation
http://www.accesswire.com/img.ashx?id=503288
Copyright 2018 ACCESSWIRE
FROM MARKETWATCH
BlackRock fund manager sees this as the market’s ‘sweet spot’
This emerging-market ETF continues to blow away the competition
Jobless claims drop 4,000 to 226,000
https://marketwatch.com/story/new-age-beverages-corporation-closes-new-475-million-financing-facility-2018-06-21
Wow, looks like our friendly short covered big league. NBEV may make our dreams come true. weeeeeeeeeeeeeeeeeeeeeeeeeeee
"$3 by July 15...probably sooner than that"....that from Joe the Master Trader, the Main Mod of this board, on Periscope: https://www.pscp.tv/w/1MnxnZBvDDNxO?q=%40chinastockpro
BPMC ...Dew, does this company have interest to you at these reduced levels? TIA.
285k share block trade earlier.
What about Bob?
Interesting article that points out the sales of legalized recreational mj in the first quarter of 2018:
https://www.fool.com/investing/2018/05/19/california-just-reduced-its-marijuana-tax-revenue.aspx
Listening to that CC last night, I think of someone bragging about their new car that can hit 200 at a drop of a hat. The only problem is that the new car owner doesn't have the cash to buy the gasoline to make that car fly. This is the situation NBEV is currently in. If demand for all of the new higher margin products is so high, where is BW going to get the money? It's not looking like it's coming from PNC. Where ever it's coming from, it's going to be at terms that will be much less attractive than what we were hoping for. Most likely, cap raises i.e. DILUTION is going to hit this stock. So the $7 share price that everyone wants to go back to is now much less likely as the float expands. It really is disappointing as I was hoping to load up a new position.
I hope they get the LOC, otherwise they will have to raise. Watching this.
Mr. covered call with all of his objectivity lmao.